Inhibikase Therapeutics, Inc. (IKT) vs SAB Biotherapeutics, Inc. (SABS)
A side-by-side comparison of Inhibikase Therapeutics, Inc. and SAB Biotherapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
IKT
Inhibikase Therapeutics, Inc.
$1.98HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
SABS
SAB Biotherapeutics, Inc.
$2.93HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — IKT vs SABS
growth of $100 · dividends reinvested · last 6yIKT -95.6% (-40.7%/yr)SABS -96.9% (-44.1%/yr)IKT compounded faster over this window
IKT SABS
IKT vs SABS: by the numbers
- •SABS is the larger company ($267M vs $261M market cap).
Metrics side by side
Valuation
| Metric | IKT | SABS |
|---|---|---|
| P/B ratio | 1.71 | 1.24 |
Profitability
| Metric | IKT | SABS |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -39.55% | -5.95% |
| ROIC | -42.92% | -31.62% |
Growth (annualized)
| Metric | IKT | SABS |
|---|---|---|
| EPS CAGR (5Y) | N/A | -50.57% |
| Total return CAGR (5Y) | -29.10% | -50.16% |
Frequently asked
- How have IKT and SABS total returns compared?
- Over the past 5 years, IKT delivered -29.10% and SABS delivered -50.16% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.